Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
RESEARCH TOOLSreports
BioMarin Pharmaceutical (BMRN) Stock Price & Analysis
1,782 Followers
BMRN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$76.02 - $99.56
Previous Close$92.06
Volume7.88M
Average Volume (3M)1.40M
Market Cap
$17.47B
Enterprise Value$17.48B
Total Cash (Recent Filing)$1.07B
Total Debt (Recent Filing)$1.09B
Price to Earnings (P/E)105.7
Beta0.64
Next Earnings
Jul 30, 2024EPS Estimate
$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.87
Shares Outstanding188,675,622
10 Day Avg. Volume1,603,226
30 Day Avg. Volume1,402,283
Standard Deviation0.09
R-Squared0.04
Alpha0.00001
Financial Highlights & Ratios
Price to Book (P/B)3.89
Price to Sales (P/S)7.11
Price to Cash Flow (P/CF)158.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.26
Enterprise Value/Gross Profit9.18
Enterprise Value/Ebitda57.28
Forecast
1Y Price Target
$111.48Price Target Upside35.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
BioMarin Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBioMarin's total revenue and adjusted EPS estimates show growth, indicating a healthy financial outlook.
Market ExpansionIndication expansion could increase Voxzogo's addressable market substantially in the US.
Product LaunchKey product Roctavian is in focus for its launch in treating severe hemophilia A, with investor expectations for patient treatment numbers being met.
Bears Say
Commercial UptakeThere are concerns about low commercial uptake for Valrox due to its variable or transient effects and the existence of an effective standard of care.
Financial GuidanceThe company did not provide specific guidance for their commercial enzyme segment, but anticipates a mid-to-high single-digit growth offset by the decline of Kuvan due to the loss of exclusivity.
Genetic Testing MarketDisconnect between obtaining genetic data and determining its immediate usefulness is a roadblock in the rapid adoption of genetic testing.
---
Ownership Overview
1.27% Insiders
40.32% Mutual Funds
19.77% Other Institutional Investors
38.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $76.02 and its highest was $99.56 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
Currently, no data Available
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Jul 30, 2024 which is in 95 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Apr 24, 2024. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.312 by $0.148.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is $0.34.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 189,775,040 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of $0.46 in its last earnings report, beating expectations of $0.312. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Among the largest hedge funds holding BioMarin Pharmaceutical’s share is PRIMECAP Management Co. It holds BioMarin Pharmaceutical’s shares valued at 2B.
---
BioMarin Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$111.48 (35.67% Upside)
$111.48 (35.67% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 26.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.15%
12-Months-Change
Fundamentals
Return on Equity
3.51%
Trailing 12-Months
Asset Growth
7.32%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
---
BMRN Company Deck
---
BMRN Earnings Call
Q1 2024
0:00 / 0:00
---
BMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
---
BMRN Stock 12 Months Forecast
Average Price Target
$111.48
▲(35.67% Upside)
Technical Analysis
Best Analysts Covering BMRN
1 Year
1 Year Success Rate
15/22 ratings generated profit
1 Year Average Return
+5.07%
reiterated a buy rating 2 months ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 68.18% of your transactions generating a profit, with an average return of +5.07% per trade.
---